Shares of Cerus Corp. (NASDAQ:CERS) saw strong trading volume on Monday . 1,583,424 shares changed hands during trading, an increase of 27% from the previous session’s volume of 1,250,927 shares.The stock last traded at $6.90 and had previously closed at $6.75.

Several brokerages recently weighed in on CERS. FBR & Co restated an “outperform” rating and set a $10.00 target price on shares of Cerus Corp. in a report on Tuesday, August 2nd. BTIG Research restated a “buy” rating and set a $10.00 target price on shares of Cerus Corp. in a report on Monday, June 20th. Cantor Fitzgerald restated a “buy” rating and set a $9.00 target price on shares of Cerus Corp. in a report on Thursday, July 7th. Robert W. Baird set a $10.00 target price on Cerus Corp. and gave the company a “buy” rating in a report on Saturday, August 6th. Finally, Zacks Investment Research cut Cerus Corp. from a “hold” rating to a “sell” rating in a report on Tuesday, August 9th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $9.10.

The firm has a 50 day moving average of $6.76 and a 200-day moving average of $6.07. The firm’s market capitalization is $708.69 million.

Cerus Corp. (NASDAQ:CERS) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($0.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by $0.01. During the same quarter last year, the firm earned ($0.17) EPS. The firm earned $9.25 million during the quarter, compared to analyst estimates of $8.88 million. The firm’s quarterly revenue was up 4.8% on a year-over-year basis. On average, equities analysts forecast that Cerus Corp. will post ($0.68) earnings per share for the current year.

In other news, CFO Kevin Dennis Green sold 17,150 shares of the business’s stock in a transaction dated Monday, August 22nd. The stock was sold at an average price of $6.80, for a total value of $116,620.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.